The United States of America As Represented by the Department of Health

The United States of America As Represented by the Secretary of

The Government of the United States of America, As Represented by the

Christopher K-h Tseng

Victor E Marquez

John S Driscoll

Hiroaki Mitsuya

James A Kelley

David G Johns

Mu-Ill Lim

Alberto Haces

Robert I Glazer

Joseph J Barchi, Jr

Harry Ford, Jr

Joseph E Tomaszewski

Methods of treating a human infected with human immunodeficiency virus (HIV), such as a human with AIDS, with the purina nucleotides 2',3'-dideoxy-2'-beta-fluoroadenosine (FddA) and 2',3'-dideoxy-2'-beta-fluoroinosine (FddI) are disclosed. These nucleotides are stable in an acid environment and thus can be used for oral administration. Methods of inhibiting human immunodeficiency virus replication in a human T cell using these purina nucleotides are also disclosed.

2',3'-dideoxy-2'-fluoro-purine nucleosides and methods for using same

Purine nucleosides active against human immunodeficiency virus which are substituted at the 2'-position by a strong electronegative group such as fluorine are stable in an acid environment and thus can be used for oral administration.

Acid stable purine dideoxynucleosides

The present invention relates, in general, to prodrugs. In particular, the present invention relates to lipophilic, aminohydrolase-activated, anti-viral nucleoside prodrug compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds.

Lipophilic, aminohydrolase-activated prodrugs

Cyclopentenyl pyrimidine compounds have potent anti-viral, anti-tumor and differentiating activity. Of these compounds, cyclopentenyl cytosine has proved to be particularly effective in a variety of tumors, as well as having good antiviral activity and potent differentiating properties.

Antiviral and anticancer cyclopentenyl cytosine

Growing community of inventors

Burtonsville, MD, United States of America

Christopher K-h Tseng